Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13778645 | 1.00 | SLC6A2 (0.37) | SLC6A2SLC6A4ALDH1A1LMNAHTT | |
| SCHEMBL14373872 | 1.00 | SLC6A2 (0.37) | SLC6A2SLC6A4ALDH1A1LMNAHTT | |
| SCHEMBL28396816 | 0.80 | ADRB2 (0.38) | SLC6A2SLC6A4LMNAHTTPDE2A | |
| SCHEMBL14400704 | 0.79 | SLC6A2 (0.39) | SLC6A2SLC6A4ALDH1A1LMNAHTT | |
| SCHEMBL21594432 | 0.79 | PDE2A (0.50) | SLC6A2SLC6A4ALDH1A1LMNAHTT | |
| SCHEMBL14047123 | 0.79 | SLC6A2 (0.39) | SLC6A2SLC6A4ALDH1A1LMNAHTT | |
| SCHEMBL13778747 | 0.79 | SLC6A2 (0.39) | SLC6A2SLC6A4ALDH1A1LMNAHTT | |
| SCHEMBL14373887 | 0.76 | PDE2A (0.37) | PDE2A | |
| SCHEMBL14383040 | 0.75 | MIF (0.57) | SLC6A2SLC6A4ALDH1A1LMNAHTT | |
| SCHEMBL13778638 | 0.72 | KMT2A (0.46) | SLC6A2SLC6A4ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192206-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | VAN LOMMEN GUY ROSALIA EUGEEN | 2009-07-30 | — | — | US | disclosed |
| US-20090192206-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | VAN LOMMEN GUY ROSALIA EUGEEN | 2009-07-30 | — | — | US | disclosed |
| US-7511068-B2 | Mercaptoimidazoles as CCR2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-7511068-B2 | Mercaptoimidazoles as CCR2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192206-A1 | MERCAPTOIMIDAZOLES AS CCR2 RECEPTOR ANTAGONISTS | CCR2, CCR1, CXCR3 | SLC6A2 1293/4885SLC6A4 1250/4885ALDH1A1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.